AI Tool Cuts Stroke Recurrence by 27% in Landmark China Trial

A large-scale trial in China has shown that an AI-driven tool can significantly improve stroke care. The system, tested across 77 hospitals, helped reduce recurrent vascular events in patients by over a quarter. Researchers say the findings highlight the potential of AI to transform secondary stroke prevention worldwide.

The study involved 21,603 stroke patients with an average age of 67, of whom 36% were women. They were admitted to hospitals using either AI-supported care or standard treatment methods. The AI clinical decision support system (CDSS) analysed complex neuroimaging data to determine stroke causes and recommend tailored therapies.

Over three months, patients managed with AI assistance experienced a 26% lower risk of further vascular incidents compared to those receiving conventional care. This improvement remained consistent over a full year, with the AI group maintaining a 27% reduction in new events. Safety checks also confirmed no increase in disability, deaths, or bleeding complications.

Hospitals using the AI tool scored higher on stroke care quality, achieving 91.4% adherence to best practices versus 89.8% in standard-care sites. The system's adaptability across different hospital IT platforms suggests it could scale globally. Yet, as of March 2026, only three countries—the US, Germany, and Japan—have issued official guidelines for AI integration in acute stroke treatment.

The trial demonstrates that AI-driven decision support can enhance stroke outcomes without compromising safety. With fewer than a handful of nations adopting such systems, the findings may encourage broader policy changes. Researchers argue that wider implementation could help close gaps in secondary stroke prevention and improve long-term patient recovery.